An Exploratory Study of Near-infrared Light Therapy for Mild to Moderate Alzheimer's Disease

Early Phase 1Not Yet RecruitingNCT06836180

Xuanwu Hospital, Beijing40 enrolled

Overview

This is an exploratory clinical study to evaluate the efficacy and safety of near-infrared light therapeutics in the treatment of mild to moderate Alzheimer's disease.

This experiment adopts a single-center, single-arm research design. All the patients who signed the informed consent were screened, and qualified subjects could only be enrolled to receive NIR therapy. This study plans to enroll 40 patients, all of whom meet the enrollment conditions will receive NIR therapy, and the treatment is arranged to be once a day, once a 30min NIR therapy, 6 times a week. The treatment lasted for 96 weeks, and follow-up and assessment were performed at baseline, 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72 weeks, 84 weeks, 96 weeks. During the first week of treatment, caregivers will be trained in the use of the NIR device, and after the training is complete, researchers will also provide remote guidance, making visits as needed. Changes in the 96-week ADAS-cog score from baseline were used as the primary endpoint to verify the efficacy and safety of the NIR device.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Alzheimer Disease

Interventions

Near infrared light therapyDEVICE

Once a day, once 30 minutes of near-infrared light treatment, 6 times a week for 96 weeks

Eligibility

Sex: ALLMin age: 50 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 50 - 90 years old, no gender limitation; * Meeting the National Institute on Aging and Alzheimer's Association (2011 NIA-AA) is likely the core clinical diagnostic criteria for Alzheimer's disease; * The MMSE score is ≥ 12 and ≤ 26; * The subjects should have primary school education or above and be able to complete the cognitive ability measurement and other tests stipulated in the protocol; * If taking cognitive-improving medications, the dose must be stable for at least 12 weeks prior to enrollment (stable for at least 4 weeks with psychotropic medications); * Participants themselves or their guardians voluntarily participate and sign the informed consent. Exclusion Criteria: * Any cognitive impairment or dementia not caused by Alzheimer's disease, or co-existing with a serious mental illness (schizophrenia, bipolar disorder, major depression, etc.); * Currently taking anticoagulant drugs; * A history of seizures or hemorrhagic stroke within 12 months; * Allergic to sunlight or visible light or high sensitivity to head and neck skin; * Severe head trauma or implants (bone nails, bone plates, excision, etc.); * Malignant tumors; * Any other medical condition that is not stabilized and adequately controlled (such as serious heart, respiratory, gastrointestinal, or kidney disease), or that the investigator believes may affect patient safety or interfere with the evaluation of the test; * Persons addicted to alcohol or drugs; * Women who are pregnant, nursing or planning a pregnancy; * Participated in other clinical studies within 1 month before participating in this trial; * Other conditions deemed unsuitable for clinical trial participation by the investigator.

Locations (1)

Xuanwu Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Outcomes

Primary Outcomes

Alzheimer's disease assessment scale-cognitive section(ADAS-Cog)

change from baseline on the Alzheimer's disease assessment scale-cognitive section(ADAS-Cog)

Time frame: baseline, 96 weeks

Secondary Outcomes

ADAS-Cog

change from baseline on the Alzheimer's disease assessment scale-cognitive section(ADAS-Cog)

Time frame: baseline,12 weeks,24 weeks,36 weeks,48 weeks, 60 weeks, 72 weeks, 84 weeks

Mini Mental state Examination (MMSE)

change from baseline on the Mini Mental state Examination (MMSE) score

Time frame: baseline,12 weeks,24 weeks,36 weeks,48 weeks, 60 weeks, 72 weeks, 84 weeks, 96 weeks

Quantification of T-cell Subpopulation Proportions in Cerebrospinal Fluid (CSF) via Single-Cell RNA Sequencing

To determine the proportional abundance of T-cell subsets (e.g., CD4+, CD8+, regulatory T cells) within the cerebrospinal fluid (CSF) of patients using single-cell RNA sequencing (scRNA-seq).

Time frame: baseline, 12 weeks

Comprehensive Profiling of Glycolytic and Lipid Metabolic Substrates in Cerebrospinal Fluid (CSF) via Metabolomics

To quantify the concentrations of key metabolites involved in glycolysis (e.g., glucose, lactate, pyruvate) and lipid metabolism (e.g., free fatty acids, acylcarnitines, phospholipids) in cerebrospinal fluid (CSF) using liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based metabolomics.

Time frame: baseline, 12 weeks

Quantification of Alzheimer's Disease (AD)-Associated Pathogenic Proteins in Cerebrospinal Fluid (CSF) via Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)

To measure the concentration of AD-related neurotoxic proteins (e.g., amyloid-beta 42 \[Aβ42\], total tau, phosphorylated tau \[p-tau181/217\], neurofilament light chain \[NfL\]) in cerebrospinal fluid (CSF) using high-sensitivity liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Central Contacts

Yi Tang, MD, PhD

CONTACT

0086+1083199456 tangyi@xwhosp.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.